NorthWest Biotherapeutics Inc (NWBO)

[Doc logic]

AVII77,

With regard to Optune, patient acceptance and quality of life considerations seem to be holding up its relevance to SOC. It seems to be an option but not necessarily an option that should be considered SOC, at least at this point, as many patients would perhaps opt out. This would seem to be a consideration FDA would weigh carefully with regard to possible alternate treatments with equal comparative benefit and better quality of life with regard to SOC as it currently exists. I'm pretty sure this would come up in their discussions don't you think?